Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Raymond James Financial, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Raymond James Financial, Inc. trades at $156.93 (market cap $30.15B). The key difference: Raymond James Financial, Inc. is far larger — about 31× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Raymond James Financial, Inc. pays a 1.38% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Raymond James Financial, Inc. for 75 Days on average.
| MRVI | RJF | |
|---|---|---|
Market Cap | $972.90M | $30.15B |
Volume | 4,325,710 | 980,106 |
Sector | Health | Financials |
52-Week High | $9.00 | $181.18 |
52-Week Low | $2.83 | $140.89 |
Typical Hold Time | 0 Days | 75 Days |
Enterprise Value | $1.08B | $24.02B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Raymond James Financial (RJF) trades at $157.25, down 0.88% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent earnings beats, revenue growth from $10.9B in 2022 to $13.84B in 2025, and robust profitability margins. Recent news highlights executive leadership changes and a declared $0.54 dividend payable in October 2026.
The stock presents a mixed outlook: attractive valuation multiples and analyst consensus price target of $178.50 suggest upside potential, but bearish technical indicators and rising expenses pose near-term risks. Investment appeal hinges on sustained earnings growth and management's execution amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
